Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 3 clinical trial titled A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease. The study aims to evaluate the efficacy and safety of retatrutide, a potential treatment for individuals with severe obesity and cardiovascular disease, over approximately 113 weeks.
Intervention/Treatment: The study is testing retatrutide, administered subcutaneously, as the primary intervention. Retatrutide is being compared to a placebo to assess its effectiveness in treating obesity and cardiovascular conditions.
Study Design: This interventional study uses a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of who receives the treatment versus the placebo. The primary purpose is treatment-focused.
Study Timeline: The study began on May 30, 2023, and is currently active but not recruiting new participants. The last update was submitted on July 22, 2025, indicating ongoing progress in the trial.
Market Implications: The progress of this study could significantly impact Eli Lilly’s stock performance, as successful results may enhance investor confidence and market position in the obesity and cardiovascular treatment sectors. Competitors in the pharmaceutical industry will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.